Navigation Links
Glenmark Announces Appointment of Mr. Philip Andrew Gioia (Phil) as President North America and Global API Business
Date:12/2/2013

MUMBAI, India, December 2, 2013 /PRNewswire/ --

Glenmark Pharmaceuticals announces the appointment of Mr. Philip Andrew Gioia (Phil) as President North America and Global API business. Phil has taken charge of his responsibilities and will be based at Mahwah, NJ, USA. He will be reporting into the Chairman & Managing Director - Mr. Glenn Saldanha. In this role Phil will be responsible for the Generics and Branded business across North America as also the Global API Sales & Marketing. Phil has over 25 years of experience in the US pharmaceutical industry both in the generics and the branded space.

     (Logo: http://photos.prnewswire.com/prnh/20130626/625083)

On his appointment, Mr. Glenn Saldanha mentions, "We believe that with Phil's rich & diversified experience across the Generics & Branded Pharmaceutical businesses as well as Business Development, brings the necessary skills & acumen to lead and grow the North American operations and the API business of Glenmark." 

Phil joins Glenmark from Bausch & Lomb (acquired by Valeant Pharmaceuticals, August 2013), where his career spanned nearly 5 years most recently as Global Head of Diversified Products and Business Development, Pharmaceuticals.  He worked significantly on expanding Bausch & Lomb's product pipeline. Prior to that, he was Division Head - Pharmaceutical Business Unit, North America. His responsibilities included all aspects of P&L management in addition to overall strategic commercial operations for the brand, generic and OTC divisions.

Preceding Bausch & Lomb, Phil enjoyed 13 years of increased responsibility at Barr Pharmaceuticals, Inc. from 1995 until January 2009 (acquired by Teva Pharmaceuticals). He joined the generic business assuming increasing levels of responsibility, then built Barr's branded business as VP/SVP of Sales which included a 300+ person sales force focused on Women's Health. In 2007, Phil was appointed Senior Vice President (SVP) of the $1.6 billion US Generic Sales & Marketing business where he was involved in the portfolio planning, manufacturing, logistics and supply chain activities.  He led the forecasting group, and was very involved in product selection, planning, and logistics; ensuring the best in class customer service with respect to supply and quality within the trade. Phil began his pharmaceutical career with Lederle Laboratories and Forest Pharmaceuticals in various sales and marketing positions.

About Glenmark

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues. (SCRIP 100 Rankings published in the year 2013). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.] and Pain [neuropathic pain and inflammatory pain].

The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has 14 manufacturing facilities in four countries and has six R&D centers. Its subsidiary, Glenmark Generics Limited services the requirements of the US and Western Europe generics markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.

Issued by: Glenmark Pharmaceuticals Limited

http://www.glenmarkpharma.com


'/>"/>
SOURCE Glenmark Pharmaceuticals Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Glenmark Pharmaceuticals Announces Launch of its Child Health CSR Programme in Kenya
2. Glenmarks Consolidated Revenue Increases by 33.96% to Rs. 13812.59 Million for Q3 FY 12-13
3. Vorsitzender & Managing Director von Glenmark Pharma - Herr Glenn Saldanha - erhielt Preis des Schweizer Botschafters für außergewöhnliche Innovation
4. Glenmarks Consolidated Revenue Increases by 18.9% to Rs. 12551.9 Mn for Q2 FY12-13
5. Endo Health Solutions Announces Receipt of Requisite Consents and Expiration of Consent Solicitations Relating to its 7% Senior Notes Due 2019, 7.00% Senior Notes Due 2020 and 7 1/4% Senior Notes Due 2022
6. Thoratec Announces Presentations At Investor Conferences For December 2013
7. QRxPharma Announces MOXDUO License Deal In Israel
8. Elbit Imaging Announces the Results of the Companys Unsecured Financial Creditors Meeting Approving the General Terms of Agreement to be Entered Into With Bank Hapoalim
9. Net Health Announces New Vice President of Training and Implementation
10. Celsion Corporation Announces Strategic Loan Facility
11. BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017  SARES•REGIS Group leased the first ... at Conejo Spectrum Business Park in ... Biotherapeutics, Inc. , a biopharmaceutical company developing meaningful ... that have been underserved by scientific innovation, with ... cancer, autoimmune and infectious disease. Before ...
(Date:4/18/2017)... Research and Markets has announced the addition ... their offering. ... devices market to grow at a CAGR of 6.35% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/18/2017)... 18, 2017 Research and Markets has ... States Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast to 2023" ... ... equipment revenues as well as growth in the number of ... value to market participants that design and manufacture molecular imaging ...
Breaking Medicine Technology:
(Date:4/21/2017)... Maine (PRWEB) , ... April 21, 2017 , ... ... today announced it’s been named Agency of Record (AOR) for Theravent, Inc. ... or eliminate snoring. Theravent’s parent company, Foundation Consumer Healthcare, is now working to ...
(Date:4/21/2017)... Arvada, CO (PRWEB) , ... April 21, 2017 ... ... health and performance system, has partnered with O2X , an active lifestyle ... are focused on improving the health of firefighters, police offers, first responders, military ...
(Date:4/21/2017)... Columbia (PRWEB) , ... April 21, 2017 , ... ... treating people who wish to overcome their mental health struggles. The Alive team uses ... Vic LeBouthillier says: “Our approach in dealing with a mental health struggle is based ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... held the much anticipated Regional Primary Care Spring Symposium on April 1, 2017 ... local medical community, offering physicians and healthcare providers an opportunity to learn about ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... quality-based imaging practices, is seeking candidates to serve on its Accreditation and ... , “RadSite’s ultimate mission is improving image quality and reducing patient ...
Breaking Medicine News(10 mins):